|
Oct 3
|
Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024
|
|
Sep 27
|
Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients
|
|
Sep 5
|
Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting
|
|
Sep 4
|
Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma
|
|
Jul 19
|
Are You Looking for a Top Momentum Pick? Why Poseida Therapeutics, Inc. (PSTX) is a Great Choice
|
|
May 14
|
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
|
|
May 9
|
Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting
|
|
May 3
|
Broker Revenue Forecasts For Poseida Therapeutics, Inc. (NASDAQ:PSTX) Are Surging Higher
|
|
May 2
|
Xyphos and Poseida to develop allogeneic cell therapies for cancer
|
|
May 1
|
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
|
|
May 1
|
Astellas adds to ‘off-the-shelf’ cell therapy capabilities with Poseida deal
|
|
Apr 18
|
Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
|
|
Apr 17
|
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
|
|
Apr 8
|
Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
|
|
Mar 25
|
Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer
|
|
Mar 19
|
Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
|
|
Mar 13
|
Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma
|
|
Mar 10
|
US$14.00 - That's What Analysts Think Poseida Therapeutics, Inc. (NASDAQ:PSTX) Is Worth After These Results
|
|
Mar 9
|
Poseida Therapeutics Full Year 2023 Earnings: Beats Expectations
|
|
Mar 8
|
Poseida Therapeutics Inc (PSTX) Reports Fourth Quarter and Full Year 2023 Financial Results
|